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ABSTRACT
Background The FIFA has implemented an important
antidoping programme for the 2014 FIFA World Cup.
Aim To perform the analyses before and during the
World Cup with biological monitoring of blood and urine
samples.
Methods All qualiﬁed players from the 32 teams
participating in the World Cup were tested out-of-
competition. During the World Cup, 2–8 players per
match were tested. Over 1000 samples were collected in
total and analysed in the WADA accredited Laboratory of
Lausanne.
Results The quality of the analyses was at the required
level as described in the WADA technical documents.
The urinary steroid proﬁles of the players were stable
and consistent with previously published papers on
football players. During the competition, amphetamine
was detected in a sample collected on a player who had
a therapeutic use exemption for attention deﬁcit
hyperactivity disorder. The blood passport data showed
no signiﬁcant difference in haemoglobin values between
out-of-competition and postmatch samples.
Conclusions Logistical issues linked to biological
samples collection, and the overseas shipment during
the World Cup did not impair the quality of the
analyses, especially when used as the biological passport
of football players.
INTRODUCTION
The Fédération Internationale de Football
Association (FIFA) introduced doping controls in
1966 to ensure a fair competition prior and during
the FIFAWorld Cup tournaments.1 The doping con-
trols of the 2014 FIFA World Cup in Brazil were
managed by the FIFA Medical Ofﬁce and the FIFA
Sports Medical Committee, as done for all the previ-
ous World Cups. Antidoping procedures were
applied in accordance with the FIFA antidoping reg-
ulations and the respective WADA International
Standards.2 3 Prior to the World Cup ﬁnals, an
extensive campaign of out-of-competition (OOC)
antidoping tests was organised to collect blood and
urine samples from individual players from the 32
qualiﬁed countries, corresponding to a total of more
than 750 OOC samples.4 This collection was the
ﬁrst step to implement the athlete biological pass-
port (ABP), a new strategy in football.5–8 During the
64 matches played in Brazil, a further 300 blood
and urine samples were collected in competition
(IC). The real effect on the blood values for the bio-
logical passport obtained after a football game has
not been really investigated until now.
This study aimed to compare the results of the
analyses for several key biological parameters
obtained in the OOC and the IC phases. This will
preview the application of the biological passport
in football. In addition, we aimed to provide a
global picture of the antidoping analyses results in
football.
METHODS
Samples collection
For the OOC testing programme, 32 teams were
tested during their training camp period, which
extended from 3 March to 6 June 2014. In total,
779 urine samples, 769 whole blood samples
(EDTA) and 773 serum samples were collected
during the OOC. All sampling procedures were
performed unannounced by a team of specially
trained doctors and nurses according to the loca-
tion of the teams. Samples from one team were
grouped into a single parcel and sent to the labora-
tory, either by courier or delivered by hand under
controlled temperature conditions as deﬁned in the
applicable regulations.2 During this precompetition
phase, most of the samples were collected during
training camps in the following countries: Austria,
Belgium, France, Greece, Italy, the Netherlands,
Norway, Portugal, Spain, Switzerland, the UK,
Argentina, Brazil, Chile, Costa Rica, Mexico, the
USA and Uruguay (ﬁgure 1).
FIFAWorld Cup 2014 took place in Brazil, from
12 June to 13 July, in 12 different venues (ﬁgure 2).
In total, 300 urine samples, 305 EDTA and 307
serum samples were taken in the IC period of 64
matches. Each football game corresponded to one
bundle was delivered to the Laboratory of
Lausanne.
Sample delivery
To ensure fair competition during the tournament,
results for tests were produced before the next
match for each team. To achieve this, the transpor-
tation schedule was prepared in advance by the
staff of the FIFA Medical Ofﬁce. The local organis-
ing committee in Brazil coordinated with courier
companies to ensure transportation conditions for
the samples as described by the International
Standard for Testing inside Brazil and overseas.
Samples were kept at a refrigerated temperature
between the collection sites and the laboratory. The
delivery time for the shipments during the competi-
tion is described in the ﬁgure 3 and table 1. All
samples arrived at the laboratory in less than 48 h,
Open Access
Scan to access more
free content
Baume N, et al. Br J Sports Med 2015;49:614–622. doi:10.1136/bjsports-2015-094762 1 of 10
Original article
allowing the whole blood samples to be analysed in time as
described in the WADA guidelines.
In table 1, the analyses turnaround time is shown. The mean
time for both urine and serum analytical reports to the FIFA
Medical Ofﬁce were made in less than 24 and 31 h, respectively.
In these conditions, all results were reported in due time, prior
to the next game for each participant in the competition.
Temperatures of blood and serum samples were measured on
the arrival in the laboratory and these met the international
standards for testing. Samples were transported under appropri-
ate refrigerated conditions.
Sample analysis
All urine samples were analysed with the established and accre-
dited antidoping analytical methods. Quantiﬁcation of the
steroid proﬁle was performed on a Hewlett Packard 6890 GC
system plus gas chromatography system coupled to a Hewlett
Packard 5973 Mass Selective Detector (Palo Alto, California,
USA) mass spectrometer. Screening analyses for the detection of
anabolic steroids (class S1) were performed on an Agilent 7890B
gas chromatography system coupled to a Triple Quadrupole
7000B (Wilmington, Delaware, USA). Both instruments were
Figure 1 Map of countries where out-of-competition samples were collected and geographical position of the Swiss Laboratory for Doping
Analyses (LAD). In Europe: Austria, Belgium, France, Greece, Italy, the Netherlands, Norway, Portugal, Spain and Switzerland. In Americas:
Argentina, Brazil, Chile, Costa Rica, Mexico, the USA and Uruguay.
Figure 2 The 12 venues in Brazil for the 2014 FIFA World Cup.
Figure 3 Delivery time of samples from the 12 venues to the
laboratory during the 2014 FIFA World Cup.
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used in standard antidoping analytical conditions.9–11 Before
injection, urine samples were prepared as follows: 20 μL of
ISTDs (methyltestosterone 200 ng/mL, testosterone-d3 80 ng/
mL, epitestosterone-d3 40 ng/mL, androsterone-d4 glucuronide
200 ng/mL and stanozolol-d3 40 ng/mL), 1 mL of boiled phos-
phate buffer (0.8M, pH 7) and 50 μL of β-glucuronidase from
Escherichia coli were added to 2.5 mL of urine. Prior to incuba-
tion, samples were left for 1 h at 50°C or overnight at 37°C
(16 h). After hydrolysis, pH was adjusted to 8.5–9 with carbonate
buffer (Na2CO3/NaHCO3 1/10, w/w) and liquid–liquid extrac-
tion (LLE) was performed with 5 mL of methyl tert-butyl ether.
The organic layer was then transferred and evaporated to
dryness, and residue was derivatised with 50 μL of MSTFA-
NH4I-ethanethiol (1000:2:3, v/w/v) at 60°C for 20 min.
Compounds of classes S3, S4, S5, S6, S7, S8 and S9 were
screened using an ACQUITY UPLC liquid chromatography
system coupled to a Xevo TQ-S triple quadrupole MS from
Waters (Milford, Massachusetts, USA). In total 100 mL of urine
were diluted with 900 mL of buffer (ultrapure H2O with 0.6 mg/
mL of mefruside as internal standard) before injecting into the
LC-MS system running under conditions previously published,12
with a modiﬁed linear gradient going from 2% to 98% of
organic phase over 6 min followed by a column re-equilibration
step at initial mobile phase conditions for 3 min. This ‘dilute
and shoot’ approach allowed the screening of the majority of
β-2 agonists, hormone and metabolic modulators, diuretics and
masking agents, stimulants and cannabinoids. Glucocorticoid
aliquots came from the sample preparation described above for
the anabolic steroids but after the LLE step, evaporation was fol-
lowed by addition of 100 mL of the mixture 80/20 H2O with
0.1% formic acid/acetonitrile to 0.1% formic acid.
The Steroidal Module of the ABP is based on the premise that
samples collected on a longitudinal basis should show an athlete’s
physiological levels of hormones unaffected by any doping prac-
tice.13 The athlete’s steroidal variables are collected and analysed
over a period of time through the usual urine tests and then the
steroid proﬁle is measured. It consists of the urinary concentra-
tions of testosterone (T), epitestosterone (E), androsterone (A),
etiocholanolone (Etio), 5α-androstan-3α,17β-diol (5αAdiol) and
5β-androstan-3α,17β-diol (5βAdiol), together with the urine
sample speciﬁc gravity (SG). T concentration is one of the six
parameters included in the steroid proﬁle. In case of abnormal
steroid proﬁles data (T/E ratio over 4.0; T concentration greater
than 200 ng/mL or concentration of A or Etio greater than
10 000 ng/mL14), the method for determining the isotopic com-
position of the relevant analytes is applied. This includes gas
chromatography, a subsequent combustion to CO2 and ﬁnally,
mass spectrometric analyses of this gas in a speciﬁc multicollector
mass spectrometer (gas chromatography combustion-isotope
ratio mass spectrometry, GC-C-IRMS). The 13C/12C ratio,
expressed in δ13C values (%), were determined for T metabolites
and compared with that of urinary reference steroids within
the sample.
Sample extraction procedures and IRMS analyses are
described as ‘procedure A’ by Saudan et al.15
Luteinizing Hormone (LH) and human chorionic gonado-
tropin (hCG) were measured once in every urine sample (OOC
and IC) using the Immulite 2000XPI instrument (Siemens
Healthcare Diagnostics Products Ltd, Llanberis, UK) and the
LH (ref. L2KLH6) and HCG kits (ref. L2KCG6). In case of
hCG conﬁrmation procedure, the intact hCG was detected by
sandwich ELISA method (Human Chorionic Gonadotropin
ELISA, ALPCO, USA).
While every urine sample was analysed, serum samples were
partly screened for erythropoiesis-stimulating agents (ESAs),
hematide and recombinant human growth hormone (rhGH).
Among the 773 serums collected during the OOC period, 65
were screened for hematide, 203 for ESAs and 198 for rhGH
whereas hematide, ESAs and rhGH were screened IC in 17, 135
and 125 samples, respectively. On reaching the laboratory,
serum samples were centrifuged and aliquoted to follow WADA
guidelines, especially regarding rhGH analyses.
Previously published hematide method16 was applied using
100 mL of serum submitted to an enzymatic digestion with sub-
tilisin and a solid phase extraction step before running on the
ultra-high performance liquid chromatography–tandem mass-
spectrometry (UHPLC-MS-MS) analytical tool as described
above from Waters.
ESAs were tested in serum samples subjected to afﬁnity puriﬁ-
cation with EPO Puriﬁcation Kit (MAIIA Diagnostics). Samples
were passed to 10% in buffer (20 mM Tris pH 7.5, 0.1 M
NaCl, 0.1% Tween 20 and 0.02% NaN3). The diluted serums
were passed through Millex GV ﬁlters (0.22 μm), puriﬁed by
immunoafﬁnity and eluated with 50 μL Desorption (low pH)
buffer. Then, pH-neutralisation was performed by addition of
5 μL adjustment buffer (0.1 M Bis-Tris pH 7.0, 0.1 M NaCl,
10 mM glycine, 0.1% Tween 20 and 0.02% NaN3).
SARCOSYL-PAGE was performed as previously described by
Reichel et al17 with minor modiﬁcations. BlotCycler technology
(Precision Biosystems, Mansﬁeld, Ohio, USA) was used for incu-
bations (blocking and antibodies) and washing steps at 4°C.
rhGH isoforms analyses were made using the WADA-
approved kits18 and by following manufacturer instructions.
Brieﬂy, 150 mL of serum were loaded with 50 mL of furnished
buffer. After incubation (2 h at room temperature), tubes were
extensively washed. A total of 200 mL of acridinium-labelled
secondary antibodies were added and incubated for 2 h. After
systematic washing, tubes were revealed with hydrogen perox-
ide. A luminometer (LB953, Berthold, Switzerland) allowed the
quantiﬁcation of the signal emitted by acridinium oxidation.
Calculation of rhGH isoforms ratio was based on the standard
curves loaded in parallel from routine samples.
The 1077 EDTA samples (771 OOC and 306 IC) were ana-
lysed after being received at the laboratory and according to the
ABP Operating Guidelines.19 Every sample was analysed twice,
on the same day, on the same haematology analyser (Sysmex
XN-2000; Sysmex Europe, Norderstedt, Germany). If the
results between two measures on the same instrument were
>0.1 g/dL for haemoglobin (HGB) and/or >0.15% for reticulo-
cytes percentage (RET%) (for values equal or below 1.00%) or
0.25% (for values above 1.00%), duplicate measurements were
repeated once again on the same analyser. Instruments were sub-
mitted to regular internal and external quality control proce-
dures as required by the Standards of Laboratory Medicine.
Table 1 Delivery times and temperatures of refrigerated boxes at
reception to the laboratory during the IC phase.
Delivery
time (h)
Temperature
at reception (°C)
TAT in hours
Urine Serum
Mean 38 h 11 min 7.7 23 h 39min 30 h 21min
Minimum 23 h 00 min 4.5 17 h 06min 16 h 11min
Maximum 44 h 00 min 13.2 47 h 44min 93 h 16min
Mean analysis turnaround time (TAT) for both urine and serum are also shown with
the minimum and maximum values.
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All FIFA biological samples were analyzed in dedicated
batches which included regular positive and negative controls as
described in the standard operating procedures which are a part
of the ISO 17025 scope of accreditation of the Swiss
Laboratory for Doping Analyses and as per procedures of the
International Standard for Laboratories.3
RESULTS
Preanalyses
Prior to initial testing procedures in the laboratory, two preana-
lytical measurements were performed on a sample: pH and SG.
As shown in ﬁgure 4A, pH is distributed normally for all urine
samples, with no value exceeding the critical value of 8.5. No
signiﬁcant difference was found between OOC and IC samples
with regard to pH and the distribution is comparable to previ-
ous results described in similar football competitions.20 21
SG was also measured on all urine samples for preanalytical
purposes and for the correction of the concentrations of
endogenous steroid metabolites according to the WADA tech-
nical document dedicated to endogenous anabolic androgenic
steroids measurement.14 This parameter also indicates the
hydration state of the player at the time of sample collection.
The distribution of the SG values for all IC and OOC urine
sample tests is shown in ﬁgure 4B. Higher SGs were measured
for the OOC urine samples (mean: 1.017) compared to the IC
samples (mean: 1.014).
OVERALL RESULTS OF ANTIDOPING ANALYSES
Clenbuterol
Among the 779 urine samples collected OOC, 4 samples, col-
lected in Mexico and Spain, showed traces of clenbuterol. Two
of these samples were reported as negative because clenbuterol
concentrations were below the reporting limit of the laboratory
(5 pg/mL) whereas the other two samples contained clenbuterol
concentration of about 50 pg/mL and were reported as adverse
analytical ﬁndings (AAF).
Tramadol and formestane
Among the samples collected OOC, 7 contained tramadol parent
compound (ranging from 16 to 5 mg/mL) and metabolite (ranging
from 130 ng/mL to 3.5 mg/mL). One urine sample contained an
abnormally high concentration of formestane (73 ng/mL).
Glucocorticoids, hCG and LH
Among the 300 IC samples, 3 contained glucocorticoids (prednis-
one and prednisolone, triamcinolone acetonide, budesonide
metabolite) above the WADA minimum required performance
limit (MRPL) of 30 ng/mL and in another sample prednisolone
was detected at a concentration below the MRPL.22 Immulite
screening quantiﬁcation of hCG revealed that one sample con-
tained hCG at a concentration of 13.6 mIU/mL. Additionally, one
sample presented an elevated LH concentration (69 mIU/mL).
Figure 4 pH (A) and speciﬁc gravity (B) of OOC and IC urine samples from the 2014 FIFA World Cup (IC, in competition; OOC, out of
competition).
Figure 5 Distribution of T concentrations (in ng/mL) in urine samples from the 2014 FIFA World Cup. (A) T concentrations without correction.
(B) T concentrations after correction with SG (IC, in competition; OOC, out of competition, SG, speciﬁc gravity; T, testosterone).
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Amphetamine
One IC sample was reported as AAF for the presence of
amphetamine at a concentration of about 600 ng/mL. However,
the presence of the substance was explained by a valid thera-
peutic use exemption (TUE) for a treatment against attention
deﬁcit hyperactivity disorder.
Endogenous steroid proﬁles
Distribution of T concentrations with and without correction
with SG is depicted in ﬁgure 5. Without correction, a high
number of samples have a T concentration in the low range of
0–10 ng/mL (ﬁgure 5A). Considering the SG distribution, as
shown in ﬁgure 4B, more samples have an SG lower than
1.020, which then produced an increase of apparent T con-
centration after correction (ﬁgure 5B). Adjustment of T con-
centrations was calculated using the formula described in the
technical document:14
Figure 6 T/E ratio distributions measured in urine collected out-of-
competition (OOC) and in competiton (IC).
Figure 7 Steroid passport and concentrations (without SG correction) of a player with a normal UGT2B17 genotype (A, androsterone; CV,
coefﬁcient of variation; E, epitestosterone; Etio, etiocholanolone; IC, in competition; LH, luteinizing hormone; OOC, out-of-competition; SG, speciﬁc
gravity; T, testosterone; 5αAdiol, 5α-androstan-3a,17β-diol; 5βAdiol, 5β-androstan-3a,17β-diol).
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Conccorrected ¼ Concmeasured  (1:020 1)=(SG 1)
The distribution observed after correction is similar to the
T/E ratio distribution illustrated in ﬁgure 6.
Nine OOC samples having a T/E ratio higher than 4.0
(ranging from 4.2 to 6.7) and one IC sample having a T/E ratio
of 4.1 were analysed by GC-C-IRMS to determine a potential
exogenous origin of T abuse. All of these were reported as nega-
tive as IRMS results clearly showed an endogenous origin of
T and/or its precursors. Steroid proﬁle data of players tested 3
times or more (OOC and IC) were integrated in the adaptive
model of the Steroidal module of the ABP. Two examples are
given in ﬁgures 7 and 8.
Haematological parameters
Whole blood samples were collected from all the qualiﬁed
players during the OOC tests and all tested players after the
games. The WADA procedures for the blood tests, as described
in the operational guidelines for the biological passport, were
entirely applied, except for the 2 h delay before blood collection
after the match. In the operating guidelines, the appendix A is
dedicated to the blood sample collection requirements.19 “If col-
lection occurs after training or Competition, test planning shall
… ensure testing does not occur within two hours of such activ-
ity…If for some reason, the Sample was taken within two hours
of training or competition, the nature, duration and intensity of
the exertion shall be recorded.”
For logistical reasons, the 2 h wait after exercise was not feas-
ible at the FIFA World Cup and, therefore, was not applied. In
fact, antidoping tests in football right after the game have
always been challenging because of the players. In principle,
blood collection is not time-consuming, in contrast to urine
sampling. For this reason, the antidoping authorities of FIFA
collect the blood tests as soon as the player arrives in the
Figure 8 Steroid passport and concentrations (without SG correction) of a player with del/del UGT2B17 genotype (A, androsterone; CV, coefﬁcient
of variation ;E, epitestosterone; Etio, etiocholanolone; IC, in competition; LH, luteinizing hormone; OOC, out-of-competition; SG, speciﬁc gravity; T,
testosterone; 5αAdiol, 5α-androstan-3α,17β-diol; 5βAdiol, 5β-androstan-3α,17β-diol).
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antidoping collection room, directly after the game. Depending
on the location of the antidoping room in the stadium and the
duration of press interviews, the time after exercise can vary
from 15 and 90 min, if the player was still on the pitch at the
end of the game. Furthermore, the nature and the duration of
participation in the competition were recorded.
Even though the World Cup tournament is not considered as
a controlled study, the data obtained on the ﬁeld can give a
good indication of the real effect of a football match on these
parameters. Figure 9 shows that the parameters measured for
the red cell lines are not signiﬁcantly different between IC and
OOC samples.
The cumulative frequency distribution curves of the haemoglo-
bin concentrations and the reticulocyte percentage, the two main
components of the blood passport (ﬁgure 10) do not show any
difference between OOC and IC samples. Contrary to what was
shown at Euro 2008,21 there was no signiﬁcant effect of the com-
petition on the values of these critical blood parameters.
Most of the players did not have more than 2–3 blood tests
(1 OOC and 1–2 IC) then it was not deemed relevant to estab-
lish a blood passport at this stage for all players. Groups of
players were established as a function of their position in the
ﬁeld and the time they played during the matches.
As observed in table 2, there is homogeneity in the blood
data between the different groups, with no signiﬁcant effect
within the groups, if the collection was done IC or OOC.
DISCUSSION
Preanalyses
The measurement of pH allowed the laboratory to check if the
urine degraded before or during the transportation process, for
example, by bacterial contamination. In the case of an elevated
pH (>8.5), the steroid proﬁle could be affected as bacterial con-
tamination was clearly described to be a confounding factor
impacting the endogenous anabolic steroid concentrations
(T and related compounds) and the proﬁle interpretation.23 24
SG was a useful parameter to evaluate the hydration status
during the competition phase, especially in hot and extreme
weather conditions. During the competition phase, the SG
results show that all players were well hydrated, which was not
necessarily the case during the OOC tests.
Clenbuterol
Clenbuterol abuse in sports is an important topic in the ﬁght
against doping as this compound is used and authorised for
animal feeding in speciﬁc countries. Meat contamination has
previously resulted in the presence of a small amount of clenbu-
terol in urine samples of tested football players as well as volun-
teers.12 25–28 Clenbuterol abuse in different countries is far
from solved and AAF in urine samples collected in different
countries, particularly in Mexico, continues to be present on a
regular basis.
Tramadol and formestane
Tramadol is part of the WADA monitoring programme and
laboratories report these cases as negative. Formestane is
Table 2 Blood passport values of players depending on their position and the time spent on the field
Position and time spent on
the field (minimum)
In competition Precompetition
n HGB (g/dL) RET (%) Off-score n HGB (g/dL) RET (%) Off-score
Defender 96 14.9 1.24 82.9 194 14.9 1.21 83.9
0–45 45 14.8 1.25 81.1
45–90 3 14.8 0.96 89.7
90–135 48 15.1 1.25 84.2
Forward 78 15.1 1.26 84.0 140 15.1 1.22 85.4
0–45 38 14.8 1.27 80.8
45–90 19 15.6 1.31 88.4
90–135 21 15.1 1.20 85.9
Goalkeeper 43 15.0 1.15 86.2 80 15.2 1.24 86.5
0–45 26 15.0 1.11 87.4
45–90 2 16.1 1.49 87.4
90–135 15 14.9 1.18 84.0
Midfielder 88 15.3 1.25 86.2 199 15.1 1.21 85.8
0–45 42 15.2 1.26 85.6
45–90 15 15.5 1.11 92.6
90–135 31 15.2 1.30 83.9
Unknown 156 15.1 1.20 85.5
Total/mean 305 15.1 1.24 84.6 769 15.1 1.21 85.3
HGB, haemoglobin; RET, reticulocyte percentage.
Figure 9 Blood parameters in OOC and IC samples. Percentage of
OOC values were calculated considering the IC data as 100% (HCT,
haematocrit; HGB, haemoglobin; IC, in competition; IRF, immature
reticulocyte fraction; MCH, mean corpuscular haemoglobin; MCHC, MCH
concentration; MCV, MC volume; OOC, out-of-competition; RBC, red
blood cell (erythrocyte) count and Ret, reticulocyte percentage.
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considered as a potent aromatase inhibitor that could minimise
side effects of anabolic steroids abuse by reducing the conver-
sion into oestrogens29 30 and therefore, it is included in the S4
class of the WADA forbidden list. Formestane could also stem
from endogenous origin.31 The WADA deﬁnes a threshold for
which additional analysis is performed to prove the endogenous
or exogenous origin of this substance. During the 2014 FIFA
World Cup in Brazil, the technical document stated that
“GC-C-IRMS analysis shall be conducted before reporting an
Adverse Analytical Finding for Samples containing formestane
at less than 150 ng/mL”.22 GC-C-IRMS conﬁrmation analysis
was performed following the method published by Piper et al30
and the results indicated an endogenous origin of formestane
leading to a negative reporting of the sample.
Glucocorticoids, hCG and LH
Glucocorticoids are part of class S9 of the WADA list32 and are
prohibited when administered by oral, intravenous, intramuscu-
lar or rectal routes. Administration through alternative routes is
justiﬁed by a TUE ruled by the dedicated WADA International
Standard for TUEs (ISTUE).33 Three urine samples contained
glucocorticoids above the MRPL; after consultation with the
FIFA Medical Board, a valid TUE was effective for all of them
and the results were reported as negative.
According to the WADA guidelines for reporting and manage-
ment of hCG ﬁndings,34 “samples producing a concentration of
total hCG above 5 mIU/mL on the Initial Testing Procedure,
laboratory shall perform a conﬁrmation procedure to quantify
intact hCG.” If the intact form concentration is still above
5 mIU/mL, the laboratory reports an AAF, otherwise an atypical
ﬁnding (ATF) report is produced. The conﬁrmation analysis was
performed on the sample containing performed 13.6 mIU/mL.
ELISA kit showed that intact hCG fell below 5 mIU/mL and
thus, the laboratory reported the sample as ATF. No threshold
has been deﬁned for LH in urine to report a case as AAF, but
high amount of urinary LH could be a marker of T or other
anabolic steroids manipulation.35 36 A close analysis of the
steroid proﬁle of this sample allowed the laboratory to consider
the case as negative.
Endogenous steroid proﬁles
The OOC distribution of the T/E ratio clearly shows the
already published bimodal ﬁgure9 37 38 which was explained
by genetic polymorphism of the enzyme involved in the
T metabolism.39–41 A complete deletion of the UGT2B17 gene
(del/del genotype) involved in the phase II (glucuronidation)
metabolism results in a decrease of urinary Texcretion and thus,
results in lower T/E ratio compared to the normal mean value
of 1–1.2. In contrast, the IC samples repartition of the T/E
ratios does not follow this bimodal distribution. This could stem
from the early disqualiﬁcation of the Asian teams after the ﬁrst
round of the tournament, as the del/del genotype has been
shown to be signiﬁcantly higher among Asian people compared
to the other ethnicities.42 43
The ABP uses the athlete’s own values rather than population
values as a basis for evaluation. The longitudinal proﬁle of spe-
ciﬁc markers (5αAdiol/5βAdiol, A/T and T/E ratios) was analysed
to determine if any atypical patterns were present. Before the
introduction of the ABP steroid module, if the T/E ratio was
greater than 4, the laboratory had to perform an IRMS analysis
to detect the use of exogenous (from outside the body) steroids.
With this ‘population reference’ approach, only high values
resulted in IRMS testing. Now, with the adaptive model, the
intraindividual variation of speciﬁc markers is considered to
perform or not to perform an IRMS test.
An important feature of the urinary steroid proﬁle is the sta-
bility of the ratios issued from steroid quantiﬁcation. Whereas
A/Etio, 5αAdiol/5βAdiol and A/T are more subjected to varia-
tions,9 the T/E ratio has proven to be stable over time.44–47 This
characteristic has been at the origin of the implementation of
the steroidal module of the ABP.8 38 48 Since January 2014, the
adaptive model is applied on all the analytical data provided by
the WADA accredited laboratories in Antidoping Administration
and Management System (ADAMS). Figures 7 and 8 depict the
longitudinal proﬁles of a ‘normal’ subject and most probably
del/del player, respectively. Even if no genotyping has been per-
formed on the players, it is highly credible that participants
with a collapsed T concentration in urine and thus with low T/
E ratio (below 0.5) are depleted in enzyme responsible for T
excretion in urine. As observed in ﬁgures 7 and 8, the adaptive
model shows stable measurement during the OOC and IC
period. The fact that all samples were analysed in the same
laboratory with the same analytical procedure favoured the sta-
bility of the ABP proﬁles. Even if the robustness and reliability
of steroid proﬁle quantiﬁcation is insured by WADA from
among all the accredited laboratories, it is a well-known fact
that variability increases when several methods and techniques
are used.23 49
Figure 10 Cumulative frequency distribution curves for haemoglobin (left panel) and reticulocytes (right panel) in the in competition (red line) and
out-of-competition (black line) samples.
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Summary
The main lesson learned from the FIFAWorld Cup 2014 were:
(1) meticulous organisation of antidoping tests on the ﬁeld and
well-controlled shipments of samples to the laboratory by the
antidoping authority does not compromise the samples. This
allows the accredited laboratory to provide valid results. (2) No
differences were observed between ou-of-competition and post-
competition for haematological values.
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